Clareo Health | Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI
Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Bordeaux
With
TEVA laboratories
This is a prospective cohort, observational, longitudinal, monocentric study. This study will include 60 patients with CIS followed for 1 year and 60 healthy subjects.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Patients:
* Men and Women
* ≥16 years
* Fluent French speaker
* Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation
* Between 60 and 180 days from the onset
* At least two clinically silent lesions on their T2-weighted brain or spinal MRI scan with a size of at least 3 mm, at least one of which being cerebral, ovoid, or periventricular
* Having a medical insurance
* Free and informed consent signed
Controls:
* Men and Women
* ≥18 years
* Fluent French speaker
* Having a medical insurance
* Free and informed consent signed
You may not be if
Patients:
* Prior documented neurological episode suggestive of MS.
* Other ongoing neurological diseases.
* Known chronic systemic diseases as judged by the investigator (for instance: lupus, Gougerot-Sjögren, sarcoidosis, sclerodermia, Crohn disease,…).
* Dosage change, stop or start of hypnotic or anxiolytic or antidepressive treatment less than 15 days
* MRI contra-indications.
* Steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily.
Controls:
* Known chronic psychiatric or neurologic diseases which could interfere with neuropsychological testing, not taking into account stable and mild depressive syndrome
* Known chronic systemic diseases as judged by the investigator (for instance: lupus, Gougerot-Sjögren, sarcoidosis, scleroderma, Crohn disease…).
* MS familial history
* Current dependence on alcohol or drugs
* Known cognitive impairment
* Prior neuropsychological testing with the same tests less than one year
* Dosage change, stop or start of hypnotic or anxiolytic or antidepressive treatment less than 2 months
* Steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily.
* MRI contra-indications
* Steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily.
